Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oleg Gluz

Showing results (1-10 of 97) with videos related to

Pageof 10
Sort By:
Current Oncology Reports|March 2, 2023
Molecular Profiling in Early ER + Breast Cancer to Aid Systemic Therapy DecisionsOleg Gluz, Monika Graeser
Breast Care (Basel, Switzerland)|December 21, 2023
HER2+ Early Breast Cancer: From Escalation via Targeted and Post-Neoadjuvant Treatment to De-EscalationMonika Graeser, Oleg Gluz
Breast (Edinburgh, Scotland)|July 2, 2017
Neoadjuvant therapy for triple negative and HER2-positive early breast cancerNadia Harbeck, Oleg Gluz
Geburtshilfe Und Frauenheilkunde|April 24, 2020
Use of Taxanes in Metastatic HER2-negative Breast Cancer - a Status ReportOleg Gluz, Cornelia Kolberg-Liedtke, Frederik Marmé, et al.
Cancer Treatment Reviews|June 18, 2010
Personalized treatment of early-stage breast cancer: present concepts and future directionsNadia Harbeck, Marwa Salem, Ulrike Nitz, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 9, 2019
CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and AbemaciclibTanja K Eggersmann, Tom Degenhardt, Oleg Gluz, et al.
Breast Care (Basel, Switzerland)|February 20, 2014
Genomic profiling in luminal breast cancerOleg Gluz, Daniel Hofmann, Rachel Würstlein, et al.
Anticancer Research|February 9, 2013
Lumpectomy versus mastopexy--a post-surgery patient surveyChristian Eichler, Marit Kolsch, Axel Sauerwald, et al.
Journal of Health Economics and Outcomes Research|July 10, 2026
Identifying Minimum Threshold Level of Trial Crossover Rates Yielding Nonsignificant Overall Survival Benefit Associated with Cancer Treatments: A Systematic Literature Review of HTA SubmissionsAnandaroop Dasgupta, Ankita Kaushik, Barinder Singh, et al.
Pathology, Research and Practice|May 29, 2016
Lobular breast cancer: Clinical, molecular and morphological characteristicsMatthias Christgen, Doris Steinemann, Elna Kühnle, et al.
Pageof 10

Showing results (1-10 of 97) with videos related to

Sort By:
Pageof 10
Current Oncology Reports|March 2, 2023
Molecular Profiling in Early ER + Breast Cancer to Aid Systemic Therapy DecisionsOleg Gluz, Monika Graeser
Breast Care (Basel, Switzerland)|December 21, 2023
HER2+ Early Breast Cancer: From Escalation via Targeted and Post-Neoadjuvant Treatment to De-EscalationMonika Graeser, Oleg Gluz
Breast (Edinburgh, Scotland)|July 2, 2017
Neoadjuvant therapy for triple negative and HER2-positive early breast cancerNadia Harbeck, Oleg Gluz
Geburtshilfe Und Frauenheilkunde|April 24, 2020
Use of Taxanes in Metastatic HER2-negative Breast Cancer - a Status ReportOleg Gluz, Cornelia Kolberg-Liedtke, Frederik Marmé, et al.
Cancer Treatment Reviews|June 18, 2010
Personalized treatment of early-stage breast cancer: present concepts and future directionsNadia Harbeck, Marwa Salem, Ulrike Nitz, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 9, 2019
CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and AbemaciclibTanja K Eggersmann, Tom Degenhardt, Oleg Gluz, et al.
Breast Care (Basel, Switzerland)|February 20, 2014
Genomic profiling in luminal breast cancerOleg Gluz, Daniel Hofmann, Rachel Würstlein, et al.
Anticancer Research|February 9, 2013
Lumpectomy versus mastopexy--a post-surgery patient surveyChristian Eichler, Marit Kolsch, Axel Sauerwald, et al.
Journal of Health Economics and Outcomes Research|July 10, 2026
Identifying Minimum Threshold Level of Trial Crossover Rates Yielding Nonsignificant Overall Survival Benefit Associated with Cancer Treatments: A Systematic Literature Review of HTA SubmissionsAnandaroop Dasgupta, Ankita Kaushik, Barinder Singh, et al.
Pathology, Research and Practice|May 29, 2016
Lobular breast cancer: Clinical, molecular and morphological characteristicsMatthias Christgen, Doris Steinemann, Elna Kühnle, et al.
Pageof 10